

Data supplement to Cristea et al. Sponsorship bias in the comparative efficacy of psychotherapy and pharmacotherapy for adult depression: meta-analysis. Br J Psychiatry doi: 10.1192/bjp.bp.115.179275

Fig. DS1. Funnel plots. (a) Trials with industry funding; (b) Trials without industry funding (with imputed studies)





Fig. DS2. Funnel plots. (a) Trials with authors with financial COI; (b) Trials with no information on financial COI (with imputed studies)



Supplement DS1

Search string and list of included studies

A. Complete search string for PubMed

("psychotherapy"[MeSH Terms] OR "psychotherap*"[All Fields] OR cbt[All Fields] OR "cognitive behavior* therap*"[All Fields] OR "cognitive behavior* therap*"[All Fields] OR "behavior* therap*"[All Fields] OR "behavior* therap*"[All Fields] OR "cognition therap*"[All Fields] OR psychodynamic[All Fields] OR "psychoanalysis"[MeSH Terms] OR "psychoanalysis"[All Fields]) OR psychoanalytic*[All Fields] OR "counselling"[All Fields] OR "counseling"[MeSH Terms] OR "counseling"[All Fields]) OR "problem-solving"[All Fields] OR "problem solving"[All Fields] OR "mindfulness"[All Fields] OR (acceptance[All Fields] AND "commitment"[All Fields]) OR "assertiveness training"[All Fields] OR "behavior* activation"[All Fields] OR "cognitive therap*"[All Fields] OR "cognitive restructuring"[All Fields] OR "metacognitive therap*"[All Fields] OR "solution-focused therap*"[All Fields] OR "self-control therap*"[All Fields] OR "self control therap*"[All Fields] OR "self-control training"[All Fields] OR "self-control training"[All Fields])

AND

("depressive disorder"[MeSH Terms] OR ("depressive"[All Fields] AND "disorder"[All Fields]) OR "depressive disorder"[All Fields] OR "depression"[All Fields] OR "depression"[MeSH Terms]) OR depressive[All Fields] OR "major depression"[All Fields] OR "major depressive disorder"[All Fields] OR "dysthymic disorder"[MeSH Terms] OR ("dysthymic"[All Fields] AND "disorder"[All Fields]) OR "dysthymic disorder"[All Fields] OR "dysthymia"[All Fields] OR dysthymic[All Fields] OR "mood disorder"[All Fields] OR "affective disorder"[All Fields])

Filters: Randomized Controlled Trial

B. List of included studies

1 Barber JP, Barrett MS, Gallop R, Rynn MA, Rickels K. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. *J Clin Psychiatry* 2012; **73**: 66–73.

2 Barrett JE, Williams JW, Oxman TE, Frank E, Katon W, Sullivan M, *et al.* Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. *J Fam Pract* 2001; **50**: 405–12.

3 Bedi N, Chilvers C, Churchill R, Dewey M, Duggan C, Fielding K, *et al.* Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. *Br J Psychiatry* 2000; **177**: 312–8.

4 Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. *Br J Psychiatry* 1997; **171**: 328–34.

5 Blom MBJ, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, *et al.* Combination treatment for acute depression is superior only when psychotherapy is added to medication. *Psychother Psychosom* 2007; **76**: 289–97.

6 Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, *et al.* Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. *J Affect Disord* 2002; **68**: 317–30.

7 David D, Szentagotai A, Lupu V, Cosman D. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, posttreatment outcomes, and six-month follow-up. *J Clin Psychol* 2008; **64**: 728–46.

- 8 Dekker JJM, Koelen JA, Van HL, Schoevers RA, Peen J, Hendriksen M, *et al.* Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. *J Affect Disord* 2008; **109**: 183–8.
- 9 DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, *et al.* Cognitive therapy vs medications in the treatment of moderate to severe depression. *Arch Gen Psychiatry* 2005; **62**: 409–16.
- 10 Dimidjian S, Hollon SD, Dobson KS, Schmalting KB, Kohlenberg RJ, Addis ME, *et al.* Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol* 2006; **74**: 658–70.
- 11 Dunlop BW, Kelley ME, Mletzko TC, Velasquez CM, Craighead WE, Mayberg HS. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. *J Psychiatr Res* 2012; **46**: 375–81.
- 12 Dunner DL, Schmalting KB, Hendrickson H, Becker J, Lehman A, Bea C. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. *Depression* 1996; **4**: 34–41.
- 13 Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, *et al.* National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. *Arch Gen Psychiatry* 1989; **46**: 971–82; discussion 983.
- 14 Faramarzi M, Alipor A, Esmaelzadeh S, Kheirkhah F, Poladi K, Pash H. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. *J Affect Disord* 2008; **108**: 159–64.
- 15 Finkenzeller DW, Zobel I, Rietz S, Schramm E, Berger M. Interpersonelle Psychotherapie und Pharmakotherapie bei Post-Stroke-Depression. *Nervenarzt* 2009; **80**: 805–12.
- 16 Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, *et al.* Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. *Psychol Med* 2011; **41**: 151–62.
- 17 Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schütze M, Scheunemann W, *et al.* Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. *Int J Neuropsychopharmacol* 2010; **13**: 31–44.
- 18 Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, *et al.* Cognitive therapy and pharmacotherapy for depression. Singly and in combination. *Arch Gen Psychiatry* 1992; **49**: 774–81.
- 19 Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 1999; **56**: 431–7.
- 20 Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, *et al.* A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. *New England Journal of Medicine* 2000; **342**: 1462–70.
- 21 Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, *et al.* Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. *Am J Psychiatry* 2007; **164**: 778–88.
- 22 Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M. A comparative trial of psychotherapy and pharmacotherapy for 'pure' dysthymic patients. *J Affect Disord* 2005; **89**: 167–75.
- 23 Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. *Arch Gen Psychiatry* 2001; **58**: 641–8.
- 24 McKnight DL, Nelson-Gray RO, Barnhill J. Dexamethasone suppression test and response to cognitive therapy and antidepressant medication. *Behavior Therapy* 1992; **23**: 99–111.
- 25 McLean PD, Hakstian AR. Clinical depression: comparative efficacy of outpatient treatments. *J Consult Clin Psychol* 1979; **47**: 818–36.

- 26 Menchetti M, Rucci P, Bortolotti B, Bombi A, Scocco P, Kraemer HC, *et al.* Moderators of remission with interpersonal counselling or drug treatment in primary care patients with depression: randomised controlled trial. *Br J Psychiatry* 2014; **204**: 144–50.
- 27 Miranda J, Chung JY, Green BL, Krupnick J, Siddique J, Revicki DA, *et al.* Treating depression in predominantly low-income young minority women: a randomized controlled trial. *JAMA* 2003; **290**: 57–65.
- 28 Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. *J Consult Clin Psychol* 2001; **69**: 942–9.
- 29 Moradveisi L, Huibers MJH, Renner F, Arasteh M, Arntz A. Behavioural activation v. antidepressant medication for treating depression in Iran: randomised trial. *Br J Psychiatry* 2013; **202**: 204–11.
- 30 Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. *Arch Gen Psychiatry* 1984; **41**: 33–41.
- 31 Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. *BMJ* 2000; **320**: 26–30.
- 32 Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. *BMJ* 1995; **310**: 441–5.
- 33 Parker G, Blanch B, Paterson A, Hadzi-Pavlovic D, Sheppard E, Manicavasagar V, *et al.* The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study. *Acta Psychiatr Scand* 2013; **128**: 271–81.
- 34 Quilty LC, McBride C, Bagby RM. Evidence for the cognitive mediational model of cognitive behavioural therapy for depression. *Psychol Med* 2008; **38**: 1531–41.
- 35 Rush AJ, Beck AT, Kovacs M, Hollon S. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. *Cogn Ther Res* 1977; **1**: 17–37.
- 36 Salminen JK, Karlsson H, Hietala J, Kajander J, Aalto S, Markkula J, *et al.* Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. *Psychother Psychosom* 2008; **77**: 351–7.
- 37 Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodriguez E, Imber SD, *et al.* Treating major depression in primary care practice. Eight-month clinical outcomes. *Arch Gen Psychiatry* 1996; **53**: 913–9.
- 38 Scott AI, Freeman CP. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. *BMJ* 1992; **304**: 883–7.
- 39 Shamsaei F, Rahimi A, Zarabian MK, Sedehi M. Efficacy of Pharmacotherapy and Cognitive Therapy, Alone and in Combination in Major Depressive Disorder. *Hong Kong Journal of Psychiatry* 2008; **18**: 76.
- 40 Sharp DJ, Chew-Graham C, Tylee A, Lewis G, Howard L, Anderson I, *et al.* A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. *Health Technol Assess* 2010; **14**: iii – iv, ix – xi, 1–153.
- 41 Sloane RB, Staples FR, Schneider LS. Interpersonal therapy vs. nortriptyline for depression in the elderly. *Clinical and pharmacological studies in psychiatric disorders Biological psychiatry - new prospects*; **1985**: 344–6.
- 42 Thompson LW, Coon DW, Gallagher-Thompson D, Sommer BR, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. *Am J Geriatr Psychiatry* 2001; **9**: 225–40.
- 43 Weissman MM, Prusoff BA, Dimascio A, Neu C, Goklaney M, Klerman GL. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. *Am J Psychiatry* 1979; **136**: 555–8.

- 44 Williams JW, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, *et al.* Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. *JAMA* 2000; **284**: 1519–26.
- 45 Zu S, Xiang Y-T, Liu J, Zhang L, Wang G, Ma X, *et al.* A comparison of cognitive-behavioral therapy, antidepressants, their combination and standard treatment for Chinese patients with moderate-severe major depressive disorders. *J Affect Disord* 2014; **152-154**: 262–7.

Table DS1 Selected characteristics of studies directly comparing psychotherapy and pharmacotherapy for adult depression

Study	Recr	Target grp	Diagn	Psych	N _{psy}	N _{sess}	Deliv	Med	N _{pha}	Study financing	COI	COI source	% AU COI	RoB ^{a)} SG AG BA ITT	Bas Sev (HRSD)	Prov
Barber, 2011	Comm	Adults	MDD	DYN	51	20	Ind	Mix/Oth	55	GOV+PHA(FM)	Y	Orig.art	60%	+ ? ++	19.43	US
Barrett, 2001	Clin	Adults	Mood	PST	80	6	Ind	SSRI	80	OTH+PHA (FM)	Y	Frank, 2011	11%	+ ? +-	14.15	US
Bedi, 2000	Clin	Adults	MDD	Couns	39	NR	Ind	Mix/Oth	44	GOV	NR		? + SR -	-	EU	
Blackburn,1997	Clin	Adults	MDD	CBT	24	16	Ind	Mix/Oth	43	GOV	NR		? ? +-	20.05	EU	
Blom, 2007	Clin	Adults	MDD	IPT	34	12	Ind	SNRI	30	GOV+PHA	NR		? ? + -	21.07	EU	
Browne, 2002	Comm	Adults	DYS	IPT	122	10	Ind	SSRI	117	GOV+PHA	NR		+ + + -	-	CA	
David, 2008	Comm	Adults	MDD	CBT REBT	56 57	20 20	Ind Ind	SSRI	57	GOV+OTH	NR		? ? ++	22.46	EU	
Dekker, 2008	Clin	Adults	MDD	DYN	59	16	Ind	Mix/Oth	44	PHA	NR		? ? +-	20.14	EU	
DeRubeis, 2005	Comm	Adults	MDD	CBT	60	14	Ind	SSRI	120	GOV+PHA(FM)	NR		? ? ++	21.52	US	
Dimidjian, 2006	Comm	Adults	MDD	CBT BAT	35 29	16 16	Ind Ind	SSRI	49	GOV+PHA(FM)	Y	Orig.art	8%	+ - ++	20.62	US
Dunlop, 2012	Comm	Adult	MDD	CBT	41	16	Ind	SSRI	39	PHA	Y	Orig.art	33%	? + + -	19.70	US
Dunner, 1996	NR	Adults	DYS	CBT	9	16	Ind	SSRI	11	NR	NR		? ? +-	15.99	US	
Elkin, 1989	Clin	Adults	MDD	IPT CBT	61 59	16 16	Ind Ind	TCA	57	GOV+OTH	NR		+ ? +-	19.57	US	
Faramarzi, 2008		Other	MDD	CBT	29	10	Grp	SSRI	30	OTH	NR		? ? SR -	-	Iran	
Finkenzeller, 2009	Other	Stroke	MDD	IPT	23	12	Grp	SSRI	24	PHA	NR		+ ? ++	21.03	EU	
Frank, 2011	Clin	Adults	MDD	IPT	160	12	Ind	SSRI	158	GOV+PHA	Y	Orig.art	40%	- - ++	20	US

Quilty, 2008	Comm	Adults	MDD	CBT	45	16	Ind	Mix/Oth	30	OTH		NR	???	-	CA
				IPT	46	16	Ind								
Parker, 2013	Comm	Adults	Mood	CBT	11	22	Ind	Mix/Oth	10	GOV+PHA(FM)	Y	Orig.art	9%	17.57	AU
Rush, 1977	Clin	Adults	MDD	CBT	19	20	Ind	TCA	22	GOV+OTH		NR	??+	-	US
Salminen, 2008	Clin	Adults	MDD	DYN	26	16	Ind	SSRI	25	GOV+OTH	Y	Indep art ^{b)}	38%	??-	+ EU
Schulberg, 1996	Adults	Clin	MDD	IPT	93	16	Ind	TCA	91	NR		NR	??+	+	US
Scott, 1992	Adults	Clin	MDD	CBT	29	16	Ind	TCA	26	GOV		NR	??+	-	EU
				Couns	29	16	Ind	TCA							
Shamsaei, 2008	Clin	Adults	MDD	CBT	40	8	Ind	SSRI	40	OTH		NR	??	SR?	- Iran
Sharp, 2010	Other	PPD	MDD	Couns	112	6	Ind	Mix/Oth	106	GOV	Y	Orig.art	42%	+++	- EU
Sloane, 1985	Other	Elderly	MDD	IPT	19	6	Ind	TCA	10	NR		NR	--+	-	US
Thompson, 2001	Comm	Elderly	MDD	CBT	36	18	Ind	TCA	33	GOV+PHA(FM)		NR	???	-	US
Weissman, 1979	Clin	Adults	MDD	IPT	23	16	Ind	TCA	20	GOV		NR	??+	-	US
Williams, 2000	Comm	Elderly	Mood	PST	113	6	Ind	SSRI	106	OTH+PHA (FM)	Y	Orig.art	13%	+++	US
Zu, 2014	Clin	Adults	MDD	CBT	30	20	Ind	SSRI	60	GOV		NR	??+	-	CH

^{a)} RoB: risk of bias according to the Cochrane Collaboration tool. SG, sequence generation; AC, allocation concealment; BA, blinding of assessors; ITT, intent-to-treat analysis to handle missing data. Ratings of “+” indicate the study has a low RoB on that criteria; ratings of “-“ indicate high RoB; “?” uncertain RoB; SR, only self-report measures

^{b)} Independent articles in order of appearance: Epstein J, Pan H, Kocsis JH, *et al.* Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. *AJP* 2006;**163**:1784–90. doi:10.1176/ajp.2006.163.10.1784; Fleischhacker WW, Eerdeken M, Karcher K, *et al.* Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. *J Clin Psychiatry* 2003;**64**:1250–7; 3.Hirvonen J, Karlsson H, Kajander J, *et al.* Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-¹¹C]WAY-100635. *Int J Neuropsychopharmacol* 2008;**11**:465–76. doi:10.1017/S1461145707008140; Rucci P, Frank E, Scocco P, *et al.* Treatment-emergent suicidal ideation

during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. *Depress Anxiety* 2011;**28**:303–9. doi:10.1002/da.20758

Abbreviations: BAT: behavioral activation therapy; Bas Sev; Baseline Severity (evaluated on the HRSD-17); CA: Canada; CH, China; CBASP: cognitive behavioral analysis system of psychotherapy; CBT: cognitive behavior therapy; Clin: recruitment from clinical samples only; Comm: (part of the) sample recruited from the community; Couns: non-directive supportive counseling; Deliv: delivery; Diagn: diagnosis; DYN: psychodynamic therapy; DYS: dysthymic disorder; EU: Europe; FM: free medication only; GOV: government funding; Grp: group format; Ind: individual format; Indep art: independent article; IPT: interpersonal psychotherapy; MAOI: Monoamine oxidase inhibitor; MDD: major depressive disorder; Med: medication; Mix/oth: other antidepressant, mix of antidepressants or protocolized treatment with antidepressants; Mood: mixed/other mood disorder (e.g., minor depression, chronic depression, melancholic depression); MS: multiple sclerosis; N_{sess}: number of sessions; N_{pha}: number of patients in the pharmacotherapy conditions; N_{psy}: number of patients in the psychotherapy condition; NR: not reported; OTH: funding by other institution; Orig.art: original article; Psych: psychotherapy; PHA: funding by a pharmacological company; PPD: post-partum depression; Prov: provenience; PST gp: PST by a general practitioner; PST n: PST by a nurse; PST: problem-solving therapy; REBT: rational emotive behavior therapy; Recr: recruitment; SNRI: Serotonin–norepinephrine reuptake inhibitor; Specific, SSRI: Selective serotonin reuptake inhibitor; SEG: supportive-expressive group therapy; TCA: Tricyclic antidepressant; US: United States; Y, yes.